Titan Pharmaceuticals, Inc.  

(Public, OTCBB:TTNP)   Watch this stock  
Find more results for OTC:TTNP
0.482
-0.015 (-3.02%)
Jan 30 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.48 - 0.50
52 week 0.44 - 0.87
Open 0.50
Vol / Avg. 378,371.00/409,102.00
Mkt cap 53.02M
P/E     -
Div/yield     -
EPS -0.02
Shares 110.00M
Beta 1.63
Inst. own 10%
Jan 12, 2015
Titan Pharmaceuticals Inc at OneMedForum SF
Dec 4, 2014
Titan Pharmaceuticals Inc at LD Micro Conference
Nov 14, 2014
Q3 2014 Titan Pharmaceuticals Inc Earnings Call
Nov 13, 2014
Q3 2014 Titan Pharmaceuticals Inc Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 78.59% 92.65%
Operating margin -81.01% -8.50%
EBITD margin - -7.48%
Return on average assets 20.91% 44.91%
Return on average equity 74.46% -
Employees 13 -
CDP Score - -

Address

Suite 505, 400 Oyster Point Blvd
SAN FRANCISCO, CA 94080
United States - Map
+1-415-2444990 (Phone)
+1-650-2444956 (Fax)

Website links

Description

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Its product development programs focus primarily on important pharmaceutical markets with significant unmet medical needs and commercial potential. Its ProNeura technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson�s disease, where maintaining stable, around the clock blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. The Company�s products are Probuphine and Fanapt (iloperidone). Its Probuphine is specifically designed for the long-term treatment of opioid dependence and utilizes ProNeura, proprietary, long-term drug delivery technology. The Company�s Fanapt (iloperidone) is an atypical antipsychotic approved by the FDA for the treatment of schizophrenia.

Officers and directors

Marc Rubin M.D. Executive Chairman of the Board
Age: 59
Sunil Ramraje Bhonsle President, Director
Age: 63
Joseph A. Akers Director
James R. McNab Jr. Director
Age: 70
Victor J. Bauer Ph.D. Independent Director
Age: 77
Eurelio M. Cavalier Independent Director
Age: 80
Hubert E. Huckel M.D. Independent Director
Age: 82